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Abstract. 
 
We have monitored fusion between cell pairs 
consisting of a single human immunodeficiency virus–1 
(HIV-1) envelope glycoprotein–expressing cell and a 
CD4
 
1
 
 target cell, which had been labeled with both a 
fluorescent lipid in the membrane and a fluorescent sol-
ute in the cytosol. We developed a new three-color as-
say to keep track of the cell into which fluorescent lip-
ids and/or solutes are redistributed. Lipid and solute 
redistribution occur as a result of opening a lipid-per-
missive fusion pore and a solute-permissive fusion pore 
 
(FP
 
S
 
), respectively. A synthetic peptide (DP178) corre-
sponding to residues 643–678 of the HIV-1
 
LAI
 
 gp120-
gp41 sequence (Wild, C.T., D.C. Shugars, T.K. Green-
well, C.B. McDanal, and T.J. Matthews. 1994. 
 
Proc. 
Natl. Acad. Sci. USA.
 
 91:12676–12680) completely in-
hibited FP
 
S
 
 at 50 ng/ml, whereas at that concentration 
there was 20–30% fusion activity measured by the lipid 
redistribution. The differences detected in lipid mixing 
versus contents mixing are maintained up to 6 h of co-
culture of gp120-41–expressing cells with target cells, 
indicating that DP178 can “clamp” the fusion complex 
in the lipid mixing intermediate for very long time peri-
ods. A peptide from the NH
 
2
 
-terminal of gp41, DP107, 
inhibited HIV-1
 
LAI
 
 gp120-gp41–mediated cell fusion at 
higher concentrations, but with no differences between 
lipid and aqueous dye redistribution at the different in-
hibitor concentrations. The inhibition of solute redistri-
bution by DP178 was complete when the peptide was 
added to the fusion reaction mixture during the first 15 
min of coculture. We have analyzed the inhibition data 
in terms of a fusion pore dilation model that incorpo-
rates the recently determined high resolution structure 
of the gp41 core.
 
T
 
he
 
 human immunodeficiency virus–1 (HIV-1)
 
1
 
 en-
velope glycoprotein is synthesized as a gp160 pre-
cursor, which is cleaved by a cellular proteinase at a
characteristic sequence to create the mature glycoproteins
gp120 and gp41 (23). Gp120 is noncovalently attached to
the extracellular domain of gp41 and mediates the binding
of the virus to appropriate host cells through interactions
with the receptor CD4 (26) and coreceptors (18). The gp41
plays an important role in fusion between virus and cell
membranes (30). The three-dimensional structure of the
ectodomain of gp41 has been modeled using the crystal
structure of influenza hemagglutinin (HA) as a conceptual
framework (20). The model predicted two regions of the
gp41 ectodomain as extended 
 
a
 
 helices. One of these, on
the NH
 
2
 
-terminal side of the molecule, was predicted to
contain a leucine zipperlike motif, whereas the other is lo-
cated in the COOH-terminal end of the gp41 ectodomain
(see Fig. 1). In the absence of gp120 and the NH
 
2
 
-terminal
fusion peptide, the ectodomain of gp41 forms a soluble
 
a
 
-helical rodlike oligomer (40). The core structure of gp41
has recently been determined by x-ray crystallography
(10, 41).
A synthetic peptide (DP178) corresponding to the
COOH-terminal ectodomain sequence (residues 643–678
of the HIV-1
 
LAI
 
 isolate) blocked 100% of virus-mediated
cell–cell fusion at 
 
,
 
5 ng/ml (measured in a syncytium for-
mation assay), and reduced infectious titer of cell-free vi-
rus 10 times at 
 
z
 
80 ng/ml (46). The mechanism of its po-
tent inhibitory effect remains to be elucidated.
The viral fusion reaction proceeds along a series of dis-
crete steps before the final event occurs that results in de-
livery of the nucleocapsid into the cell (3, 42, 43). In previ-
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: CMAC, 7-amino-4-chloromethylcou-
marin; DiI, 1,1
 
9
 
-dioctadecyl-3,3,3
 
9
 
3
 
9
 
-tetramethylindocarbocyanine perchlor-
ate; DiO, 3,3
 
9
 
-dioctadecyloxaocarbocyanine perchlorate; FP
 
L
 
, lipid-permis-
sive fusion pore; FP
 
S
 
, solute permissive fusion pore; HA, hemagglutinin;
HIV-1, human immunodeficiency virus type–1; IC
 
50
 
, 50% effective inhibi-
tory concentration; RBCs, red blood cells.
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ous studies of cell fusion mediated by influenza HA an
important new intermediate, the fusion pore, was revealed
by the differential dispersion of lipid molecules, small
aqueous molecules, and large molecules (34), and by ca-
pacitance patch clamping studies (37, 48). Using analytical
and quantitative video microscopy we have established the
sequence of these events during HA-induced fusion with
fluorescently labeled red blood cells (RBCs) (6). Our re-
sults indicate that lipid mixing and transfer of large solutes
are sequential events occurring with different probabilities
(6, 36). We have analyzed the kinetics of events that occur
as a result of transitions between a lipid-permissive fusion
pore (FP
 
L
 
) and a solute-permissive fusion pore (FP
 
S
 
) (6).
Based on the hypothesis that HIV-1 envelope glycopro-
tein–induced fusion pore dilation follows a similar pattern
as that seen with HA, we reasoned that DP178 might be
used to dissect these various stages of fusion pore dilation.
In this report, we evaluate the ability of DP178 to block
HIV-1 envelope glycoprotein-mediated cell–cell fusion by
two different methods, the gene reporter fusion assay (32)
and fluorescent dye transfer analyzed by video microscopy
(33, 39). We developed a new three-color assay to assess
lipid and solute movement from the same target cell into
an envelope-expressing cell. We find that DP178 blocks
movement of large molecules at a 10-fold lower concentra-
tion than lipid mixing. We analyze these findings in terms
of a model for gp120-gp41–mediated fusion pore dilation.
 
Materials and Methods
 
Cells
 
The human lymphoid cell line TF228.1.16 (19) (a gift from Z.L. Jonak,
SmithKline and Beecham, Philadelphia, PA), which constitutively ex-
presses HIV-1 envelope glycoprotein, GP4F cells (a gift from J.M. White,
University of Virginia, Charlottesville, VA), mouse 3T3 fibroblasts, which
constitutively express influenza HA (16, 31), and the CD4
 
1
 
 lymphocyte
cell line SupT1 (obtained from the AIDS Research and Reference Re-
agent Program, Division of AIDS, National Institute of Allergy and Infec-
tious Diseases, National Institutes of Health, Bethesda, MD) were used.
The cells were propagated in RPMI 1640 (for human cell lines) or DME
(for GP4F) media supplemented with 10% FCS and antibiotics (Gibco
BRL, Life Technologies Inc., Gaithersburg, MD). Cell cultures were
maintained at 37
 
8
 
C in a humidified 5% CO
 
2
 
 atmosphere.
 
Reagents
 
The fluorescent probes DiI (1,1
 
9
 
-dioctadecyl-3,3,3
 
9
 
3
 
9
 
-tetramethylindocar-
bocyanine perchlorate; excitation/emission [ex/em] 550/565 nm), DiO
(3,3
 
9
 
-dioctadecyloxaocarbocyanine perchlorate; ex/em 484/501 nm), cal-
cein-AM (ex/em 496/517 nm), and CMAC (7-amino-4-chloromethylcou-
marin; ex/em 354/469 nm) were all products from Molecular Probes (Eugene,
OR). NP-40, the substrate CPRG (chlorophenol red–
 
b
 
-galactopyrano-
side), X-Gal (5-bromo-4-chloro-3-indolyl-
 
b
 
-
 
d
 
-galactopyranoside), and 
 
b
 
-galac-
tosidase from 
 
Escherichia coli
 
 (600 U/mg) were obtained from Boehrringer
Mannheim (Indianapolis, IN). Diluent C and 1-
 
b
 
-
 
d
 
-arabinofuranosylcy-
tosin (Ara-C) were purchased from Sigma Chemical Co. (St. Louis, MO).
 
Peptide Synthesis
 
The DP178 peptide (Fig. 1) was synthesized by the solid phase method
with Fmoc chemistry using a peptide synthesizer (430A; Applied Biosys-
tems, Inc., Foster City, CA). Cleavage of the peptide from the resin and
removal of the side chain–protecting groups were carried out using re-
agent K. The peptide was purified by HPLC on a Vydac C-8 column with
0.05% TFA/water-acetonitrile. The mass of the peptide (
 
M
 
r
 
 
 
5
 
 4,451) was
confirmed by electrospray ionization mass spectrometry on a Finnigan
MAT SSQ 7000 (Finnigan MAT, San Jose, CA).
 
Gene Reporter Fusion Assay
 
Recombinant vaccinia (vCB21R and vTF7.3, respectively, provided by
Dr. E.A. Berger, National Institutes of Allergy and Infectious Diseases,
Bethesda, MD) was used to express 
 
b
 
-galactosidase under the control of
the T7 promoter in TF228 cells, and T7 polymerase in SupT1 cells (18).
Cells were infected at a multiplicity of infection of 10 for 1.5 h at 37
 
8
 
C, fol-
lowed by incubation at 31
 
8
 
C overnight. For the fusion assay, 2 
 
3
 
 10
 
5
 
 cells
of each type were mixed in 96-well plates for 2 h at 37
 
8
 
C in presence of
Ara-C to reduce background. To quantitate fusion, the cells were lysed
with NP-40 to a final concentration of 0.5%, and aliquots of this lysate
were monitored for 
 
b
 
-galactosidase activity at 37
 
8
 
C using the colorimetric
assay (32).
 
Dye Transfer Fusion Assay
 
The second method used for detecting cell–cell fusion was based on the
redistribution of fluorescent probes between effector and target cells upon
fusion (33, 39). The application of three different probes was used to mon-
itor lipid versus cytosolic mixing in the same cell population.
 
Labeling with the Lipophilic Probes. 
 
DiI and DiO are the most widely
used lipophilic carbocyanine membrane probes. Their spectral properties
are independent of the alkyl chains, but are determined by the heteroat-
oms in the terminal ring systems and the length of the connecting bridge.
DiI has excitation and emission spectra compatible with rhodamine filter
sets, whereas the DiO analogue can be used with the FITC optical filter
set. This enables the study of lipid mixing between pairs of cells labeled
differently with either dye. Cells were incubated for 15 min with the probe
in RPMI/Diluent C 1:0.6 (final concentration 
 
5
 
 34 
 
m
 
M) at room tempera-
ture, shaking in the dark. The cells were then washed three times with
RPMI, changing tubes for each wash, and then resuspended at 10
 
6
 
 cells/ml
in RPMI.
 
Calcein-AM Labeling. 
 
Cells were incubated with 0.5 
 
m
 
M of calcein-AM
for 45 min at 37
 
8
 
C, washed, incubated in fresh medium for 30 min at 37
 
8
 
C,
washed twice, and then resuspended at 10
 
6
 
 cells/ml in RPMI.
 
CMAC Loading. 
 
This blue fluorescent dye freely passes through cell
membranes and then reacts with free sulfhydryls, producing a cell-imper-
meant reaction product. Cells were loaded with 20 
 
m
 
M of CMAC in
RPMI for 45 min at 37
 
8
 
C, washed, incubated in fresh medium for 30 min
at 37
 
8
 
C, washed twice, and then resuspended at 10
 
6
 
 cells/ml in RPMI.
 
Fusion Assay. 
 
Fluorescently labeled gp120-41–expressing cells and
CD4
 
1
 
 cells were cocultured at 1:1 ratio (10
 
5
 
 cells of each type) for 2 h at
37
 
8
 
C in coated microwells (MatTek Corp., Asland, MA), with different
concentrations of peptide. Bright field and fluorescent images were ac-
quired using an Olympus IX70 microscope coupled to a CCD camera
(Princeton Instruments, Trenton, NJ) with 
 
3
 
40 UplanApo oil immersion
objective. “FITC” (exciter: BP470-490; beamsplitter: DM505; emitter
BA515-550), “rhodamine” (exciter: BP530-550; beamsplitter: DM570;
emitter BA590), and “DAPI” (exciter: D360/40; beamsplitter: 400DCLP;
emitter: D450/60) optical filter cubes were carefully chosen to avoid spill-
over when observing fluorescence of the three dyes. For each sample,
three different fields were collected, and data were analyzed by overlaying
the images using Metamorph software (Universal Imaging Corporation,
West Chester, PA). When using two dyes, effector and target cells were
labeled with different probes. The total number of cells positive for one or
two dyes was scored. Bright field images were used to eliminate false
overlaying positives. 
The percentage of fusion was calculated as the mean of 
 
a
 
 and 
 
b
 
: 
 
a
 
 
 
5
 
 100
 
3
 
 (number of cells positive for two dyes/number of target cells positive for
one dye); 
 
b
 
 
 
5
 
 100 
 
3
 
 (number of cells positive for two dyes/number of ef-
Figure 1. Amino acid sequence and schematic representation of
the localization of DP178 in the gp41 protein (46).
Sequence (36 amino acids):
H2N-YTSLIHSLIEESQNQQEKNEQELLELDK-
WASLWNWF-COOH. 
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fector cells positive for one dye). If three probes were used, TF228 cells
were labeled with the cytoplasmic probe CMAC and the target cells,
SupT1, with both calcein (cytoplasmic) and DiI (lipophilic). The total
number of cells positive for one, two, or three dyes was scored. The per-
centage of lipid mixing was calculated as the mean of 
 
c
 
 and 
 
d
 
: 
 
c
 
 
 
5
 
 100 
 
3
 
(number of cells positive for DiI and CMAC/number of target cells posi-
tive for DiI and calcein); 
 
d
 
 
 
5
 
 100 
 
3
 
 (number of cells positive for DiI and
CMAC/number of effector cells positive for CMAC). The percentage of
cytoplasm mixing was calculated as the mean of 
 
e
 
 and 
 
f
 
: 
 
e
 
 
 
5
 
 100 
 
3
 
 (num-
ber of cells positive for three dyes/number of target cells positive for DiI
and calcein); 
 
f
 
 
 
5
 
 100 
 
3
 
 (number of cells positive for three dyes/number of
effector cells positive for CMAC).
Dye transfer between GP4F cells and labeled RBCs was monitored as
described previously (6, 31, 34, 37, 48).
 
Results
 
Inhibition of Cell–Cell Fusion by DP178
 
In the first set of experiments, we assayed the concen-
tration-dependent inhibitory effect of DP178 on cell–cell
fusion using the gene reporter assay (32). TF228 cells
(infected with the vaccinia recombinant vCB21R that ex-
presses 
 
b
 
-galactosidase under the control of the T7 pro-
moter) and SupT1 cells (infected with vTF7.3 vaccinia
with T7 polymerase gene) were incubated with different
concentrations of peptide as described in Materials and
Methods. After 2 h of incubation, the extent of cell–cell fu-
sion was calculated as percentage of 
 
b
 
-galactosidase activ-
ity compared with the control without peptide. The results
are summarized in Table I 
 
A.
 
 As shown, 2.5 ng/ml of pep-
tide reduced 
 
.
 
50% of cell–cell fusion as measured by
 
b
 
-galactosidase activity, and 50 ng/ml blocked the activity
completely.
The gene reporter assay monitors transfer of large mole-
cules (e.g., RNA polymerase) between cells. We were also
interested in examining the effect of the peptide on earlier
stages of fusion pore dilation. This can be done by moni-
toring transfer of lipid fluorophores incorporated into ef-
fector and target cell membranes. For convenience we will
designate the fusion pore that allows lipid transfer as FP
 
L
 
and the fusion pore that allows transfer of large solutes as
FP
 
S
 
 (6). vCB21R-infected TF228 cells were labeled with the
lipophilic probe DiI, and vTF7.3-infected SupT1 with DiO,
and upon dye redistribution cells were stained with both
dyes. As DiI and DiO are both lipophilic probes, dye
transfer will reflect lipid mixing. Table I 
 
B
 
 shows the lipid
redistribution at different concentrations of peptide. The
results indicate a significantly different effect of the pep-
tide on lipid mixing as compared to transfer of large mole-
cules. At 50 ng/ml peptide, the inhibition of 
 
b
 
-galactosi-
dase activity was almost complete, whereas there was 30%
of fusion activity measured by the lipid redistribution assay.
 
Lipid Mixing Versus Cytoplasm Mixing
 
To examine whether the differences in inhibition by
DP178 of lipid mixing and transfer of large molecules (Ta-
ble I) were because of the different methods used, we
monitored lipid mixing and cytoplasmic mixing in the
same cells. Effector cells were labeled with CMAC, a dye
that reacts with free sulfhydryl groups inside the cell, and
the target cells were labeled with both calcein and DiI.
The lipophilic probe DiI was chosen instead of DiO be-
cause it exhibits red fluorescence, whereas DiO is green
like calcein. When only DiI is redistributed to the CMAC-
labeled cells, these cells are scored as positive for lipid
mixing; cells labeled with all three dyes were positive for
both lipid and cytoplasmic mixing. Fig. 2 shows a montage
of video images from a typical redistribution experiment
using three dyes. Images were taken after 2 h of incubation
 
Table I. Inhibition of HIV-1–mediated Cell–Cell Fusion by
DP-178 Peptide
 
Peptide
concentration
(A)
 
b
 
-Galactosidase activity
(B)
DiI/DiO transfer
 
ng/ml % %
 
0 100 100
0.5 109 
 
6
 
 12.7 104.5 
 
6
 
 4.5
2.5 49.05 
 
6
 
 1.3 79.6 
 
6
 
 6.4
5 24.4 
 
6
 
 3.4 41.5 
 
6
 
 16.4
25 12.5 
 
6
 
 2.7 34.9 
 
6
 
 9.6
50 1.15 
 
6
 
 0.8 31.7 
 
6
 
 9.1
100 N.D. 20.5 
 
6
 
 4.0
500 2.5 
 
6
 
 3.6 N.D.
 
Values were calculated as mean 6 SD of two independent experiments in A, and of
three experiments in B. For data in A, b-galactosidase activity was detected according
to the gene reporter assay. After 2 h of incubation in 96-microwell plates, the percent-
age of cell–cell fusion was calculated from the enzymatic activity of the control (0 ng/
ml of peptide). For data in B, TF228 cells were labeled with DiI, and SupT1 cells with
DiO; percentage of cell–cell fusion was calculated from the control as described in
the text. N.D., not determined.
Figure 2. Inhibitory effect of DP178 peptide detected by the
three-color assay. TF228 cells were labeled with the cytosolic
probe CMAC, and SupT1 with both the lipophilic probe DiI and
the cytosolic dye calcein, and cocultured at 378C for 2 h. Images
were acquired as described in the text with an Olympus IX70 mi-
croscope. The images are acquired in bright field and in fluores-
cence, using the “DAPI” (CMAC), “rhodamine” (DiI), and
“FITC” (Calcein) optical filter cubes, respectively. The character-
istics of the filter cubes are listed in the Materials and Methods
section. The figure shows fields of a representative experiment.
(a) 50 ng/ml peptide. Two cells in contact are presented in bright
field. The one in the left (TF228) was originally labeled with
CMAC; the cell in the right (SupT1) was labeled with DiI in the
membrane and calcein in the cytoplasm. The DiI image shows the
transfer of the lipophilic probe from the upper cell to the lower
while the hydrophilic probes have not moved. (b) No peptide.
This cell has the three dyes indicating complete fusion.The Journal of Cell Biology, Volume 140, 1998 318
in presence of 50 ng/ml DP178 (Fig. 2 a) or in absence of
peptide (Fig. 2 b), and are shown in bright field and in flu-
orescence, using the DAPI (for CMAC), rhodamine (for
DiI), and FITC (for calcein) optical filter cubes, respec-
tively. The characteristics of the filter cubes are listed in
the Materials and Methods section. In Fig. 2 a (50 ng/ml
peptide), two cells in contact are presented in bright field.
The one in the left (TF228) was originally labeled with
CMAC; the cell in the right was labeled with DiI in the
membrane and calcein in the cytoplasm. It is clear from
the DiI image that the lipophilic probe has been trans-
ferred from the upper cell to the lower, whereas the hydro-
philic probes have not moved, indicating lipid redistribu-
tion only. In the sequence presented in Fig. 2 b (no
peptide) one single cell is shown labeled with the three
dyes as result of complete fusion of two cells.
We averaged data from hundreds of cell pairs similar to
those shown in Fig. 2 and plotted the average percentage
cell fusion based on redistribution of lipid and cytoplasmic
fluorophores, respectively. Fig. 3 a shows that DP178 in-
hibits cytoplasmic mixing nearly completely at 50 ng/ml
peptide at which concentration there is still z30% lipid
mixing. However, lipid mixing could be completely inhib-
ited at 1,000 ng/ml peptide (Fig. 3 a, inset) indicating that
the peptide does not exhibit nonspecific lipid mixing–
inducing characterisitics. To exclude the possibility that
the effects seen with DP178 might be due to the scoring
procedure in our assays, or that they might have a trivial
explanation such as a change in surface density of active
gp120-gp41, we have performed the same experiments
with the synthetic peptide DP107 corresponding to the
leucine zipper motif of gp41 (44). This peptide has been
shown to inhibit HIV-1 envelope glycoprotein fusion, al-
beit at higher concentrations as compared to DP178 (44).
Fig. 3 b shows the inhibition, with no differences between
lipid and aqueous dye redistribution at the different inhib-
itor concentrations. This experiment clearly demonstrates
that the difference we see in lipid and contents mixing is
specific for DP178. Moreover, we have confirmed the ob-
servation made by Lu and coworkers (25) with peptides
equivalent to DP178 and DP107, that the inhibitory effect
of DP178 is markedly reduced in the presence of stoichio-
metric amounts of DP107 (data not shown).
To exclude the possibility that the mixing in the pres-
ence of high concentrations of DP178 is because of non-
specific transfer of the membrane dyes, we expressed a
construct in which amino acids at the gp120-gp41 junction
were deleted, and proteolytic cleavage of gp160 did not oc-
cur. The uncleaved gp160 is inserted into the plasma mem-
brane and binds soluble CD4, but cannot trigger fusion
(15). BJAB cells (an Epstein-Barr virus–immortalized B
lymphocytic cell line used to construct TF228 cells [19])
were infected with vaccinia recombinant vCB16 (10 multi-
plicity of infection), which expresses the uncleaved gp160
(7). These cells were labeled with CMAC and mixed with
calcein-DiI–labeled SupT1. Experiments were performed
in parallel with BJAB cells infected at the same multiplicity
of infection with the vaccinia recombinant vSC60, which
expresses the mature envelope glycoprotein from HIV-1
IIIB strain (7). After 2 h of coculture at 378C, the samples
were analyzed for dye transfer by video microscopy. The
percentage of DiI transfer was 2.32 6 5.2 (mean 6 SD of
five data sets) of control, indicating that the 20–30% dye
transfer in the presence of 100 ng/ml peptide (Fig. 3 a) is
not because of nonspecific effects. As an additional con-
trol for nonspecific dye transfer mediated by DP178 we
have examined the effect of the peptide on dye transfer
between GPF4 cells (HA-expressing cells) and RBCs (6,
31, 34, 37, 48). Table II clearly shows that the peptide does
not induce nonspecific lipid transfer in this system. Neither
does the peptide inhibit HA-induced fusion.
Kinetics of DP178 Peptide Inhibition
To study the kinetics of the inhibitory effect of DP178 on
HIV-1 envelope glycoprotein-mediated cell–cell fusion,
vCB21R-infected TF228 cells and vTF7.3-infected SupT1
cells were cocultured at 1:1 ratios in 96-microwell plates.
Figure 3. Comparison of lipid mixing versus cytoplasmic mixing.
TF228 cells were labeled with the cytosolic probe CMAC, and
SupT1 with both the lipophilic probe DiI and the cytosolic dye
calcein. After 2 h of incubation at 378C, cells positive for the
three dyes were scored as positive for cytoplasm mixing, and cells
positive for DiI and CMAC as positive for lipid mixing only. The
percentage of cell–cell fusion in both cases is relative to the con-
trol without peptide. For every sample, three different fields were
acquired. Data are the mean 6 SD of two or three independent
experiments. d, lipid mixing; s, cytoplasm mixing. (a) Plot for
DP178. Solid line, curve-fit to the lipid mixing data according to
Eq. 1 with e 5 1.35 and KI 5 14.4 ng/ml; dashed line, curve-fit to
the cytoplasm mixing data according to Eq. 1 with e 5 2.06 and KI
5 0.96 ng/ml. Inset, same plot for DP178 at concentrations up to
1,000 ng/ml. (b) Plot for DP107. Solid line, curve-fit to the lipid
and aqueous mixing data according to Eq. 1 with e 5 8.5 and KI 5
185 ng/ml.
Table II. Effects of DP178 in Fusion between GP4F Cells
and RBCs*
GP4F cells pH DP178 Fluorescent GP4F**
ng/ml %
HA0 7.4 0 0
HA0 7.4 50 0
HA 7.4 0 3.1 6 4.38
HA 7.4 50 0
HA 5.0 0 74.4 6 9.5
HA 5.0 50 76.9 6 8.77
*DiI-labeled RBCs were added to plated GP4F cells (16, 31). For cleavage of HA0,
neuraminidase (1 U/ml) and trypsin (5 mg/ml) were added to the HA-expressing cells
(31). Samples at pH 7.4 were incubated for 2 h at 378C; samples at pH 5.0 were acti-
vated for 1 min at low pH, and then incubated for 30 min at 378C.
**Percent of GP4F cells bound to at least one RBC, which have been stained with
DiI. Data are mean 6 SD of two independent experiments.Muñoz-Barroso et al. HIV-1 Fusion Pore Dilation 319
50 ng/ml of peptide was added to effector/target mixtures
at different times after the initiation of coculture. After 2 h
of incubation at 378C, the extent of cell–cell fusion was cal-
culated as percentage of b-galactosidase activity of con-
trol. Fig. 4 shows that the fusion was completely inhibited
when the peptide was added to the fusion reaction mixture
during the first 15 min of coculture. When the peptide was
added at later time points, the inhibitory effect of DP178
was reduced, and no inhibitory response was detected if
the peptide was added .75 min after mixing.
We have studied the kinetics of fusion in absence and
presence of DP178 for up to 6 h of incubation of TF228
cells with SupT1 cells using the three color assay (see Ma-
terials and Methods). Cells expressing HIV-1 envelope
glycoprotein were labeled with CMAC, and CD4 express-
ing cells were labeled with both DiI and calcein. The same
number of cells were cocultured in absence or presence of
three different concentrations of DP178: 2.5, 25, and 50 ng/
ml, for 1 to 6 h. Cell fusion was calculated as the percent of
control without peptide. As can be seen in Fig. 5, the dif-
ferences detected in lipid mixing versus contents mixing are
maintained in the frame time studied. This indicates that
the peptide can “clamp” the fusion complex in the inter-
mediate (i.e., lipid mixing) state for very long time periods.
Discussion
The first step in the HIV-1 fusion reaction is a conforma-
tional change in the envelope glycoprotein that results in
exposure of specific epitopes in gp41 (27, 35). Synthetic
peptides corresponding to sequences of specific domains
on gp41 (Fig. 1) have been used to examine fusion mecha-
nisms (27). This paper describes experiments in which we
have studied the effects of the synthetic peptides DP178
and DP107 in HIV-1 envelope glycoprotein–mediated cell
membrane fusion. Our measurements of the inhibitory ef-
fect of the peptides on redistribution of lipids and of large
solutes inform us about the various stages of the fusion
cascade (4).
In the case of influenza HA–catalyzed fusion, a se-
quence of events has been resolved after the conforma-
tional changes. These include transfer of fluorescent-
labeled lipid molecules because of the merging of the
outer membrane monolayers (hemifusion) (22), and trans-
fer of large, aqueous fluorescent dye molecules because of
formation and expansion of a fusion pore (6, 42, 43, 48).
We have denoted these events as the opening of a FPL and
a FPS, respectively (6). Hemifusion is predicted by the
“stalk-pore” model (12) to involve intermixing of lipids
between contacting leaflets but not between noncontact-
ing membrane leaflets. The task of the viral envelope gly-
coprotein is to produce sufficient curvature in the lipid bi-
layer to create the hemifusion and fusion pore structures.
To complete fusion a lipidic fusion pore of critical radius
has to form and expand in the contact bilayer. Mutations
in various domains of influenza HA were found to have a
profound effect on the outcome of the fusion cascade. Re-
placement of the membrane-spanning domain of HA with
a glycosylphosphatidylinositol anchor results in a very sta-
ble hemifusion intermediate (22, 28). Furthermore, spe-
cific single site mutations in the fusion peptide of HA were
found not to affect lipid redistribution but significantly im-
paired the ability of HA to mediate delivery of large aque-
ous molecules from RBCs to HA-expressing cells (36).
Even in the case of fusion of wild-type HA-expressing
cells with labeled RBCs at optimal pH and temperature
only z40% of fusion events that cause lipid mixing result
in redistribution of large solutes (36, 37) a phenomenon
dubbed by Melikyan et al. as “stunted fusion” (28a).
We have not observed stunted fusion in the case of the
gp120-gp41–expressing TF228 cells incubated with SupT1
cells at 378C for up to 6 h. However, addition of 50 ng/ml
of a COOH-terminal peptide from the gp41 ectodomain
(DP178 [46]) fully blocks complete fusion (contents mix-
ing), at which concentration 30% of lipid mixing was still
in effect. Lipid mixing was completely blocked at 1,000 ng/
ml peptide. Interestingly, the NH2-terminal peptide DP107,
which inhibits at a higher dissociation constant Ki, showed
no distinction between the effects on lipid and contents
mixing. This indicates that inhibition by DP178 is not be-
cause of some trivial effect, such as reducing the surface
density of active gp120-gp41. Previous studies on inhibi-
Figure 4. Time dependence
of the inhibitory effect of
DP178 peptide. vCB21R-
infected TF228 cells and
vTF7.3-infected SupT1 were
cocultured at 1:1 ratios in 96-
wells plates (4 3 105, total
number of cells by well). 50
ng/ml of peptide was added
to effector/target mixtures at
t 5 0, and at different times
after the initiation of cocul-
ture. After 2 h of total incu-
bation at 378C, the percentage of cell–cell fusion was calculated
according to the gene reporter fusion assay. Data are mean 6 SD
of three independent experiments.
Figure 5. Kinetics of fusion in presence of DP178. TF228 cells
were labeled with the cytosolic probe CMAC, and SupT1 with
both the lipophilic probe DiI in the membrane and the cytosolic
dye calcein. The cells were cocultured at 378C for 1–6 h in ab-
sence (control) or presence of of 2.5, 25, or 50 ng/ml of DP178.
Cell fusion was calculated as a percent of control as described in
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tion of syncytia by DP178 using the same isolate (HIV-
1LAI) (46) yielded 50% inhibitory concentration (IC50) val-
ues in the range of 0.5–1.7 ng/ml. Since this is in the range
of inhibition of FPS reported here, it appears that there are
no substantial barriers between opening of the large fusion
pore and completing the fusion process (14). Interestingly,
cell fusion escapes inhibition by the peptide when it is
added up to 15 min after incubation of the cells (Fig. 4).
We have recently shown that conformational changes in
cell surface–expressed gp120-gp41 occur within 1 min of
interaction of envelope-expressing cells with appropriate
target cells (21). These observations taken together indi-
cate that the peptide acts after a conformational change of
the envelope glycoprotein.
We have interpreted our observations on inhibition of
gp120-gp41–mediated fusion on the basis of recently de-
termined high resolution crystal structures of the HIV-1
gp41 core (10, 41), which is a bent-in-half, antiparallel, het-
erotrimeric coiled-coil structure. Interestingly, a trimeric
envelope glycoprotein structure had previously been pro-
posed for HIV-1 on the basis of biochemical cross-linking
and sedimentation studies (38). Comparison with the crys-
tal structures of the influenza HA2 subunits in a low pH–
induced conformation (8) and of fragments of the Molo-
ney murine leukemia virus fusion protein (17) reveals
common structural motifs, which provide growing support
for the “spring-loaded” type of mechanistic models (9). In
this scenario, activation of the fusion protein results in re-
lease of the fusion peptide and extension of the central
coiled-coil structure. The new positioning of the fusion
peptides at the tip of the stalk provides for easy contact
with the target cell membrane. A small group of proximal
fusion proteins that are simultaneously inserted into both
the viral and target membranes would constitute a poten-
tial fusion site. A concerted collapse of this protein com-
plex, actuated by the bending-in-half of the stalks at a
central hinge region and formation of the antiparallel six-
helical bundle seen in the crystal structures, would posi-
tion the COOH-terminal transmembrane anchors and
NH2-terminal fusion peptides on top of each other in the
center. This would bring the two membranes into contact,
and thus allow for formation of the hemifusion intermedi-
ate and eventually the fusion pore (Fig. 6). The DP178 in-
hibitor, which is a peptide fragment of the COOH-termi-
nal helix seen in the crystal structures (10, 41), presumably
acts by binding to the triple-stranded coiled-coil of NH2-
terminal helices. If it displaces the COOH-terminal helices
and prevents formation of a sufficiently bent-in-half struc-
ture (as described above), then the membranes would
never get close enough for fusion to commence.
It has been proposed that an assembly of viral envelope
glycoprotein oligomers could form a molecular scaffold re-
sponsible for bringing the viral membrane close to the tar-
get cell membrane, and create the architecture that en-
ables lipid bilayers to merge (1, 2, 5, 42). Such scaffolds
have also been proposed for exocytotic fusion pores (29).
Figure 6. Schematic structural
model of the effect of DP178 on the
membrane fusion process. (a) Top
view of six, semi-aggregated gp41
trimers sticking straight up, in the
initial stage of forming a potential
fusion site (FS) complex. (b) Top
view of lipid-mixing fusion site
(FPL). The six gp41 proteins have
undergone the bending-in-half
transition, and are in the six-helical
bundle, heterotrimeric coiled-coil
conformation observed in the crys-
tal. The NH2-terminal regions of
the gp41 ectodomain are in ma-
genta, and the COOH-terminal re-
gions are in blue. The aggregate of
magenta helices at the center are
the NH2-terminal fusion peptides
inserted into the target cell mem-
brane (note that the target mem-
brane has been removed to reveal
the protein complex). A side view
of this structure is shown in the in-
sert (f). This includes the target cell
membrane (top), and shows the initial contact of the alkyl cores of the two membranes (which allows for interchange of the lipids and
leads to hemifusion). Also seen in the side view are the COOH-terminal transmembrane domains in the viral membrane. (c) Top view
of the disrupted protein scaffold, which allows for expansion of the pore and contents mixing (FPS). The transition from a to d repre-
sents binding of DP178 (green) to the low affinity site on gp41, which prevents formation of the heterotrimeric coiled-coil structure, and
thus all subsequent stages of fusion. The transition from b to e represents binding of DP178 to the high affinity site, which clamps the
protein subunits together, and prevents the transition from the lipid-mixing (FPL) to the solute-mixing (FPS) stages. The protein models
shown in b, c, e, and f were developed from a recently determined crystal structure of gp41 fragments in the heterotrimeric coiled-coil
conformation (10) (1AIK.pdb). The lengths of the NH2- and COOH-terminal helices were expanded as suggested by experimental stud-
ies of the complex in solution (25). The loops in the structures are simply placed in arbitrary positions, and were included solely to test
the steric feasibility of the models.Muñoz-Barroso et al. HIV-1 Fusion Pore Dilation 321
Movement of the viral glycoproteins away from the FPL
scaffold would break the hemifusion diaphragm, and allow
for the flow of solutes between aqueous compartments (6).
An analysis of data relating the lag phase for the onset of
HA-mediated fusion to the density of HA in the donor
membrane suggests that a minimum of 3–4 HA trimers is
required to induce a fusion event (13). Our kinetic data on
influenza HA fusion pore dilation indicate that six HA trimers
need to move to form a FPS (6). The putative transitions be-
tween fusion site, FPL and FPS are diagramed in Fig. 6.
Using this concept we have developed a model for inhi-
bition of FPL and FPS formation by DP178 (see Appendix
1). Assuming a Poissonian distribution of fusion pores
over the contact area between cells, the fraction of FPL or
FPs is then given by: 
(1)
where [I] is the concentration of inhibitor, and KI is the
concentration of I where half of the fusion sites are inhib-
ited and e reflects the efficiency of conversion from fusion
site to fusion pore. Fitting the data from Fig. 3 a (DP178)
to Eq. 1 yields e 5 1.35, KI 5 14.4 ng/ml, and e 5 2.06, KI
5 0.96 ng/ml for FPL and FPS, respectively. Fitting the data
from Fig. 3 b (DP107) to Eq. 1 yields e 5 8.5 and KI 5 185
ng/ml for both FPL and FPS.
The large difference in inhibition constants in the case
of DP178 is consistent with the notion that there are dif-
ferent binding sites for this peptide on gp41 with different
values of KI (Fig. 6). Since the inhibitory effect of DP178
works against different isolates of HIV-1 but not of HIV-2
(45, 46), it is not likely that the low affinity site represents
nonspecific binding to the cell membrane leading to inhi-
bition of cell fusion. Moreover, using labeled DP178 we
have only observed binding to HIV-1 envelope expressing
cells (unpublished results). Based on the structural infor-
mation about the gp41 core, an obvious choice for the low
affinity site (affecting both FPL and FPS formation) is the
leucine zipper domain (10, 11, 24, 25, 41, 47); with helical
DP178 peptides binding in the same way as the corre-
sponding amino acid sequence regions of the three protein
COOH-terminal helices in the crystal structures. At this
position the peptides would sterically block the regular
binding of the COOH-terminal helices to the inner core of
NH2-terminal helices, and thus prevent formation of the
bent-in-half, antiparallel, heterotrimeric coiled-coil struc-
ture presumably required to bring the viral and target cell
membranes into contact for fusion (as described above).
Similarly, the lower-affinity binding of DP107 to the
COOH-terminal domains would inhibit formation of this
structure in an inverse manner, thus also precluding all
stages of membrane fusion.
However, at certain intermediary concentrations of
DP178, we find that it is possible to fully block the ex-
change of solutes (FPS), while still having significant ex-
change of lipids (FPL). Thus, binding of the peptide to the
high affinity site is taken to be associated with the transi-
tion from the FPL to FPS states (Fig. 6). Since this transi-
tion (which constitutes breaking of the hemifusion dia-
phragm and expansion of the fusion pore) is believed to
result from disruption of the oligomeric fusion protein
scaffolding, the DP178 inhibitor is envisioned forming
links between adjacent subunits that stabilize the complex.
p 1 exp – e/1 ( I [] / K I )] + – [ =
This concept is speculatively illustrated in Fig. 6 e, in which
the NH2- and COOH-terminal ends (as short helices) of
six DP178 peptides (green) simultaneously bind to all the
adjacent gp41 proteins in the complex. In this working
model the small helices of DP178 displace the ends of the
outer gp41 COOH-terminal helices that are in the coiled-
coil complex (blue), and bind in the grooves between the
inner NH2-terminal helices (magenta). It should be noted,
however, that there is no physical evidence for the de-
picted conformation of the DP178 peptides, nor for the
binding site on gp41; rather, this simply illustrates the
steric feasibility of a single peptide linking adjacent pro-
tein oligomers. Nevertheless, this model is consistent with
the experimental results of Wild and coworkers (47), in
which deletion of only one to four residues from either the
NH2 or COOH-terminal ends of DP178 significantly re-
duced the fusion inhibition activity. As seen in Fig. 6 e, this
is because such deletions would diminish the interactions
(and thus the binding constant) between the inhibitor and
gp41. Additionally, having two regions of the peptide (i.e.,
the NH2 and COOH-terminal ends) bind the two putative
sites on the heterotrimer would make for a larger effective
binding affinity than for each region individually. This
could explain the higher observed binding constant for
blocking formation of FPS than for FPL. This model also il-
lustrates the hypothesis that, in contrast to the low affinity
site, the bound DP178 does not prevent the close contact
of the fusion peptides and COOH-terminal viral mem-
brane anchors presumed to be required for merging of the
membranes. It should be emphasized that the high affinity
binding site model shown in Fig. 6 e is only one of many
possibilities. For example, an alternative class of models
would have the link between adjacent gp41 stalks made by
an aggregate of DP178 peptides. Obviously, more detailed
experimental studies are needed to identify the sites of in-
hibitor peptide binding to the fusion proteins.
These data and analysis also form the basis for an expla-
nation why fusion of intact virus (infectivity) is inhibited
by DP178 at a concentration .10-fold higher than needed
for inhibition of cell–cell fusion (46). Since the envelope
glycoproteins in the intact virus are tightly packed, DP178
might not be able to access the interoligomer space in the
FPL site to form the clamp. However, binding of DP178 to
the leucine zipper domain, which according to our data oc-
curs with similar affinity to that seen for inhibition of viral
infectivity, will have a profound effect on fusion of intact
virus.
Appendix
An FS (see Fig. 6) is assembled according to 
, (A1)
where V is the concentration of envelope glycoprotein oli-
gomer on the surface, n is the number of Vs per fusion site.
Assuming that the concentrations of receptor (R) and
coreceptor (C) on the target cell are in excess of V, then
FS 5V/n. If the inhibitor (I) interacts with the oligomer ac-
cording to V 1 I ÛVI, with an equilibrium constant KI,
the concentration of free envelope glycoprotein (V) is
given by:
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, (A2)
where VT is the total concentration of envelope glycopro-
tein.
Assuming a Poissonian distribution of fusion pores over
a contact area between cells, the probability p(i) of i fusion
pores in the contact area is given by:
, (A3)
where l 5 aFS is the average number of fusion pores in
the contact area, FS is the number of fusion sites in the
contact area, and a the efficiency of conversion from fu-
sion site to fusion pore. Redistribution of lipid and/or large
solute will occur if at least one fusion pore opens. The
probability of such an event is given by (see reference 36):
. (A4)
Substituting aFS for l, V/n for FS, and Eq. A2 for V
yields:
(A5)
where e 5 aVT/n. Eq. A5 is the same as Eq. 1 in the main
text.
We thank Dr. E. Berger for vaccinia recombinants, Dr. Z. Jonak for the
TF228 line, and Dr. J.M. White for GP4F cells. We are also grateful to Dr.
D. Dimitrov, A. Puri, P. Hug, T. Korte, and P. Jones for careful reading of
the manuscript and helpful suggestions. 
The work was supported by the AIDS Intramural Targeted Antiviral
Program. I. Muñoz-Barroso is a postdoctoral fellow of the Direccion Gen-
eral de Investigacion Cientifica y Enseñanza Superior, Spain.
Received for publication 4 June 1997 and in revised form 26 November
1997.
References
1. Bentz, J., H.Ellens, and D. Alford. 1990. An architecture for the fusion site
of influenza hemagglutinin. FEBS (Fed. Eur. Biochem. Soc.) Lett. 276:1–5.
2. Blumenthal, R. 1988. Cooperativity in viral fusion. Cell. Biophys. 12:1–12.
3. Blumenthal, R., and D.S. Dimitrov. 1997. Membrane fusion. In Handbook
of Physiology. J.F. Hoffman, and J.C. Jamieson, editors. Oxford Univer-
sity Press, New York. 569–604.
4. Blumenthal, R., C. Schoch, A. Puri, and M.J. Clague. 1991. A dissection of
steps leading to viral envelope protein-mediated membrane fusion. Ann.
NY Acad. Sci. 635:285–296.
5. Blumenthal, R., C.C. Pak, Y. Raviv, M. Krumbiegel, L.D. Bergelson, S.J.
Morris, and R.J. Lowy. 1995. Transient domains induced by influenza
haemagglutinin during membrane fusion. Mol. Membr. Biol. 12:135–142.
6. Blumenthal, R., D.P. Sarkar, S. Durell, D.E. Howard, and S.J. Morris.
1996. Dilation of the influenza hemagglutinin fusion pore revealed by the
kinetics of individual cell–cell fusion events. J. Cell Biol. 135:63–71.
7. Broder, C.C., and E.A. Berger. 1995. Fusogenic selectivity of the envelope
glycoprotein is a major determinant of human immunodeficiency virus
type 1 tropism for CD41 T-cell lines vs. primary macrophages. Proc.
Natl. Acad. Sci. USA. 92:9004–9008.
8. Bullough, P.A., F.M. Hughson, J.J. Skehel, and D.C. Wiley. 1994. Structure
of influenza haemagglutinin at the pH of membrane fusion. Nature. 371:
37–43.
9. Carr, C.M., and P.S. Kim. 1993. A spring-loaded mechanism for the confor-
mational change of influenza hemagglutinin. Cell. 73:823–832.
10. Chan, D.C., D. Fass, J.M. Berger, and P.S. Kim. 1997. Core structure of
gp41 from the HIV envelope glycoprotein. Cell. 89:263–273.
11. Chen, C.H., T.J. Matthews, C.B. McDanal, D.P. Bolognesi, and M.L.
Greenberg. 1995. A molecular clasp in the human immunodeficiency vi-
rus (HIV) type 1 TM protein determines the anti-HIV activity of gp41
derivatives: implication for viral fusion. J.Virol. 69:3771–3777.
12. Chernomordik, L.V., G.B. Melikyan, and Y.A. Chizmadzhev. 1987.
Biomembrane fusion: a new concept derived from model studies using
two interacting planar lipid bilayers. Biochim. Biophys. Acta. 906:309–
352.
13. Danieli, T., S.L. Pelletier, Y.I. Henis, and J. M. White. 1996. Membrane fu-
sion mediated by the influenza virus hemagglutinin requires the con-
certed action of at least three hemagglutinin trimers. J. Cell. Biol. 133:
559–569.
VV T /1 ( I [] / K I ) + =
pi () l
i
e
l –
/ i ! =
p 1 exp l – () – =
p 1 exp e/1 ( I [] / K I )] . + – [ – =
14. Dimitrov, D.S., and R. Blumenthal. 1994. Photoinactivation and kinetics of
membrane fusion mediated by the human immunodeficiency type 1 en-
velope glycoprotein. J.Virol. 68:1956–1961.
15. Earl, P.L., S. Koenig, and B. Moss. 1991. Biological and immunological
properties of human immunodeficiency virus type 1 envelope glycopro-
tein: analysis of proteins with truncations and deletions expressed by re-
combinant vaccinia viruses. J.Virol. 65:31–41.
16. Ellens, H., J. Bentz, D. Mason, F. Zhang, and J.M. White. 1990. Fusion of
influenza hemagglutinin-expressing fibroblasts with glycophorin-bearing
liposomes: role of hemagglutinin surface density. Biochemistry. 29:9697–
9707.
17. Fass, D., S.C. Harrison, and P.S. Kim. 1996. Retrovirus envelope domain at
1.7 angstrom resolution. Nat. Struct. Biol. 3:465–469.
18. Feng, Y., C.C. Broder, P.E. Kennedy, and E.A. Berger. 1996. HIV-1 entry
cofactor: functional cDNA cloning of a seven-transmembrane, G pro-
tein-coupled receptor. Science. 272:872–877.
19. Fu, Y.K., T.K. Hart, Z.L. Jonak, and P.J. Bugelski. 1993. Physicochemical
dissociation of CD4-mediated syncytium formation and shedding of hu-
man immunodeficiency virus type 1 gp120. J.Virol. 67:3818–3825.
20. Gallaher, W.R., J.M. Ball, R.F. Garry, M.C. Griffin, and R.C. Montelaro.
1989. A general model for the transmembrane proteins of HIV and other
retroviruses. AIDS Res. Hum. Retroviruses. 5:431–440.
21. Jones, P., T. Korte, and R. Blumenthal. 1998. Conformational changes in
cell surface HIV-1 envelope glycoproteins are triggered by cooperation
between cell surface CD4 and coreceptors. J. Biol. Chem. 273:404–409.
22. Kemble, G.W., T. Danieli, and J.M. White. 1994. Lipid-anchored influenza
hemagglutinin promotes hemifusion, not complete fusion. Cell. 76:383–
391.
23. Kowalski, M., J. Potz, L. Basiripour, T. Dorfman, W.C. Goh, E. Terwill-
iger, A. Dayton, C. Rosen, W. Haseltine, and J. Sodroski. 1987. Func-
tional regions of the envelope glycoprotein of human immunodeficiency
virus type 1. Science. 237:1351–1355.
24. Lawless, M.K., S. Barney, K.I. Guthrie, T.B. Bucy, S.R. Petteway, Jr., and
G. Merutka. 1996. HIV-1 membrane fusion mechanism: structural stud-
ies of the interactions between biologically-active peptides from gp41.
Biochemistry. 35:13697–13708.
25. Lu, M., S.C. Blacklow, and P.S. Kim. 1995. A trimeric structural domain of
the HIV-1 transmembrane glycoprotein. Nat. Struct. Biol. 2:1075–1082.
26. Maddon, P.J., A.G. Dalgleish, J.S. McDougal, P.R. Clapham, R.A. Weiss,
and R. Axel. 1986. The T4 gene encodes the AIDS virus receptor and is
expressed in the immune system and the brain. Cell. 47:333–348.
27. Matthews, T.J., C. Wild, C.H. Chen, D.P. Bolognesi, and M.L. Greenberg.
1994. Structural rearrangements in the transmembrane glycoprotein after
receptor binding. Immunol. Rev. 140:93–104.
28. Melikyan, G.B., J.M. White, and F.S. Cohen. 1995. GPI-anchored influenza
hemagglutinin induces hemifusion to both red blood cell and planar bi-
layer membranes. J. Cell Biol. 131:679–691.
28a. Melikyan, G.B., S.A. Brener, D.C. Ok, and F.S. Cohen. 1997. Inner but
not outer membrane leaflets control the transition from glycosylphos-
phatidylinositol-anchored influenza hemagglutinin-induced hemifusion
to full fusion. J. Cell Biol. 136:995–1005.
29. Monck, J.R., and J.M. Fernandez. 1996. The fusion pore and mechanisms
of biological membrane fusion. Curr. Opin. Cell Biol. 8:524–533.
30. Moore, J.P., B.A. Jameson, R.A. Weiss, and Q.J. Sattentau. 1993. The
HIV-cell fusion reaction. In Viral Fusion Mechanisms. J. Bentz, editor.
CRC Press. Boca Raton. 233–289.
31. Morris, S.J., D.P. Sarkar, J.M. White, and R. Blumenthal. 1989. Kinetics of
pH-dependent fusion between 3T3 fibroblasts expressing influenza he-
magglutinin and red blood cells. Measurement by dequenching of fluo-
rescence. J. Biol. Chem. 264:3972–3978.
32. Nussbaum, O., C.C. Broder, and E.A. Berger. 1994. Fusogenic mechanisms
of enveloped-virus glycoproteins analyzed by a novel recombinant vac-
cinia virus-based assay quantitating cell fusion-dependent reporter gene
activation. J.Virol. 68:5411–5422.
33. Puri, A., S.J. Morris, P. Jones, M. Ryan, and R. Blumenthal. 1996. Heat-
resistant factors in human erythrocyte membranes mediate CD4-depen-
dent fusion with cells expressing HIV-1 envelope glycoproteins. Virol-
ogy. 219:262–267.
34. Sarkar, D.P., S.J. Morris, O. Eidelman, J. Zimmerberg, and R. Blumenthal.
1989. Initial stages of influenza hemagglutinin-induced cell fusion moni-
tored simultaneously by two fluorescent events: Cytoplasmic continuity
and lipid mixing. J. Cell Biol. 109:113–122.
35. Sattentau, Q.J., and J.P. Moore. 1991. Conformational changes induced in
the human immunodeficiency virus envelope glycoprotein by soluble
CD4 binding. J. Exp. Med. 174:407–415.
36. Schoch, C., and R. Blumenthal. 1993. Role of the fusion peptide sequence
in initial stages of influenza hemagglutinin-induced cell fusion. J. Biol.
Chem. 268:9267–9274.
37. Spruce, A.E., A. Iwata, J.M. White, and W. Almers. 1989. Patch clamp
studies of single cell-fusion events mediated by a viral fusion protein. Na-
ture. 342:555–558.
38. Weiss, C.D., J.A. Levy, and J.M. White. 1990. Oligomeric organization of
gp120 on infectious human immunodeficiency virus type 1 particles. J.Vi-
rol. 64:5674–5677.
39. Weiss, C.D., S.W. Barnett, N. Cacalano, N. Killeen, D.R. Littman, and J.M.Muñoz-Barroso et al. HIV-1 Fusion Pore Dilation 323
White. 1996. Studies of HIV-1 envelope glycoprotein-mediated fusion us-
ing a simple fluorescence assay. AIDS. 10:241–246.
40. Weissenhorn, W., S.A. Wharton, L.J. Calder, P.L. Earl, B. Moss, E. Ali-
prandis, J.J. Skehel, and D.C. Wiley. 1996. The ectodomain of HIV-1 env
subunit gp41 forms a soluble, alpha-helical, rod-like oligomer in the ab-
sence of gp120 and the N-terminal fusion peptide. EMBO (Eur. Mol.
Biol. Organ.) J. 15:1507–1514.
41. Weissenhorn, W., A. Dessen, S.C. Harrison, J.J. Skehel, and D.C. Wiley.
1997. Atomic Structure of the Ectodomain from HIV-1 gp41. Nature.
387:426–428.
42. White, J.M. 1992. Membrane fusion. Science. 258:917–924.
43. White, J.M. 1995. Membrane fusion: the influenza paradigm. Cold Spring
Harbor Symp. Quant. Biol. 60:581–588.
44. Wild, C., T. Oas, C. McDanal, D. Bolognesi, and T. Matthews. 1992. A syn-
thetic peptide inhibitor of human immunodeficiency virus replication:
correlation between solution structure and viral inhibition. Proc. Natl.
Acad. Sci. USA. 89:10537–10541.
45. Wild, C., T. Greenwell, and T. Matthews. 1993. A synthetic peptide from
HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS
Res. Hum. Retroviruses. 9:1051–1053.
46. Wild, C.T., D.C. Shugars, T.K. Greenwell, C.B. McDanal, and T.J. Mat-
thews. 1994. Peptides corresponding to a predictive alpha-helical domain
of human immunodeficiency virus type 1 gp41 are potent inhibitors of vi-
rus infection. Proc. Natl. Acad. Sci. USA. 91:9770–9774.
47. Wild, C., T. Greenwell, D. Shugars, L. Rimsky-Clarke, and T. Matthews.
1995. The inhibitory activity of an HIV type 1 peptide correlates with its
ability to interact with a leucine zipper structure. AIDS Res. Hum. Retro-
viruses. 11:323–325.
48. Zimmerberg, J., R. Blumenthal, D.P. Sarkar, M. Curran, and S.J. Morris.
1994. Restricted movement of lipid and aqueous dyes through pores
formed by influenza hemagglutinin during cell fusion. J. Cell Biol. 127:
1885–1894.